Full text is available at the source.
Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data
Male sexual problems linked to GLP-1 receptor agonist medications: analysis of safety report data
AI simplified
Abstract
Among 182 cases identified, 43.9% involved patients using GLP-1 receptor agonists for diabetes.
- GLP-1 receptor agonists are linked to reported instances of male sexual dysfunction, including orgasmic dysfunction, erectile dysfunction, and decreased libido.
- The majority of affected patients were aged 40-60 years.
- Exenatide was associated with 24.2% of reports, while semaglutide accounted for 21.4%.
- Statistically significant results were noted (P < 0.0001), but the overall association with sexual dysfunction is considered weak based on low reporting odds ratios.
- Monitoring of GLP-1 receptor agonist use may be necessary as their prescription increases, despite the low overall patient risk.
AI simplified